ROCHESTER, Minn. — Mayo Clinic Comprehensive Cancer Center researchers will present more than 30 studies at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting advances in precision oncology, early cancer detection, artificial intelligence (AI) and personalized cancer care. The meeting will be held May 29–June 2 at the McCormick Place Convention Center in Chicago.
Featured research includes biomarker-driven treatments for bladder and lung cancers, new approaches for triple-negative breast cancer, multicancer early detection testing, and AI-enabled analysis of the tumor microenvironment in colon cancer.
Highlighted presentations include:
Education Session: Triple-Negative Breast Cancer in 2026: Translating New Data into Clinical Decisions
Presentation time: May 30, 4:45–5 p.m. CDT
Presentation title: Stage 1 Triple-Negative Breast Cancer: Who Needs What Treatment?
Presenter: Roberto Leon-Ferre, M.D., associate professor of oncology
Poster Session: Gastrointestinal Cancer — Colorectal and Anal
Presentation time: May 30, 9 a.m.–Noon CDT
Presentation title: Health-related quality of life (HRQOL) in the phase 3 trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage 3 deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502, ATOMIC) (Abstract 2636)
Presenter: Amylou Dueck, Ph.D., professor of biostatistics
Poster Session: Gastrointestinal Cancer — Colorectal and Anal
Presentation time: May 30, 9 a.m.–Noon CDT
Presentation title: A deep learning approach to quantify tumor microenvironment features associated with postoperative ctDNA status and outcomes in a phase 3 FOLFOX-based adjuvant colon cancer trial (N0147; Alliance) (Abstract 3525)
Presenter: Frank Sinicrope, M.D., professor of medicine and oncology
Poster Session: Care Delivery/Models of Care
Presentation time: May 30, 9 a.m.–Noon CDT
Presentation title: Fertility concerns, counseling and preservation in AYA females with early-stage breast cancer: Chemotherapy receipt and timing (Abstract 1564)
Presenter: Bolun Liu, M.D., assistant professor of medicine
Education Session: It's 2026: Updates in Small Cell Lung Cancer — No Longer Too Small to Ignore
Presentation time: May 31, 8–8:15 a.m. CDT
Presentation title: Systemic Therapy for Small Cell Lung Cancer: Standard of Care and Recent Therapeutic Advances
Presenter: Rami Manochakian, M.D., associate professor of medicine
Case-Based Panel Session: Biomarker Treatment Strategies for Bladder Cancer: Putting the Patient at the Center
Presentation time: May 31, 8–9 a.m. CDT
Presentation title: Surgical Oncologist Perspective
Presenter: Mark Tyson II, M.D., professor of urology
Oral Abstract Session: Prevention, Risk Reduction and Genetics
Presentation time: May 31, 9:45–9:51 a.m. CDT
Presentation title: Safety and performance results from PATHFINDER 2, a registrational study of a multicancer early detection (MCED) test in an intended-use population (Abstract LBA10509)
Presenter: Karthik Giridhar, M.D., assistant professor of oncology
Poster Session: Gynecologic Cancer
Presentation time: June 1, 9 a.m.–Noon CDT
Presentation title: Development of an endometrial cancer test from a vaginal swab (Abstract 5624)
Presenter: Jamie Bakkum-Gamez, M.D., professor of obstetrics and gynecology
Poster Session: Breast Cancer — Local/Regional/Adjuvant
Presentation time: June 1, 1:30–4:30 p.m. CDT
Presentation title: A randomized phase 2 trial of folate receptor alpha peptide vaccine in early-stage triple-negative breast cancer (Abstract 536)
Presenter: Kathryn Ruddy, M.D., professor of oncology
Poster Session: Breast Cancer — Metastatic
Presentation time: June 1, 1:30–4:30 p.m. CDT
Presentation title: Quality of life and treatment tolerability of Bria-IMT + CPI in metastatic breast cancer (Abstract 1107)
Presenter: Saranya Chumsri, M.D., professor of oncology
Oral Abstract Session: Hematologic Malignancies — Leukemia, Myelodysplastic Syndromes, and Allotransplant
Presentation time: June 2, 9:57–10:09 a.m. CDT
Presentation title: RALLY-MF: Initial efficacy of a phase 2 study of DISC-0974, an anti-hemojuvelin antibody, to treat anemia in myelofibrosis (Abstract 6501)
Presenter: Naseema Gangat, M.B.B.S., professor of medicine and co-author Ayalew Tefferi, M.D., professor of medicine and Barbara Woodward Lips Professor II
###
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.
About Mayo Clinic Comprehensive Cancer Center
Designated as a comprehensive cancer center by the National Cancer Institute, Mayo Clinic Comprehensive Cancer Center is defining the cancer center of the future, focused on delivering the world's most exceptional patient-centered cancer care for everyone. At Mayo Clinic Comprehensive Cancer Center, a culture of innovation and collaboration is driving research breakthroughs in cancer detection, prevention and treatment to change lives.